These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31077412)

  • 1. The rationale of dose-response curves in selecting cancer drug dosing.
    Martin JH; Dimmitt S
    Br J Clin Pharmacol; 2019 Oct; 85(10):2198-2204. PubMed ID: 31077412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
    Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
    Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.
    Lucas CJ; Martin JH
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S78-S98. PubMed ID: 28921641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring.
    Knezevic CE; Clarke W
    Ther Drug Monit; 2020 Feb; 42(1):6-19. PubMed ID: 31568180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical application of drug dosing schedules in cancer therapy--Part II.
    Reich SD
    Cancer Nurs; 1984 Feb; 7(1):59-61. PubMed ID: 6559098
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature.
    Fahmy A; Hopkins AM; Sorich MJ; Rowland A
    Expert Opin Drug Metab Toxicol; 2021 Jul; 17(7):803-821. PubMed ID: 34278936
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy dosing part II: alternative approaches and future prospects.
    Kaestner SA; Sewell GJ
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):99-107. PubMed ID: 17355104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboplatin therapeutic monitoring in preterm and full-term neonates.
    Veal GJ; Errington J; Hayden J; Hobin D; Murphy D; Dommett RM; Tweddle DA; Jenkinson H; Picton S
    Eur J Cancer; 2015 Sep; 51(14):2022-30. PubMed ID: 26232270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The past, present, and future of chemotherapy with a focus on individualization of drug dosing.
    DeRidder L; Rubinson DA; Langer R; Traverso G
    J Control Release; 2022 Dec; 352():840-860. PubMed ID: 36334860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose Finding Versus Speed in Seamless Immuno-Oncology Drug Development.
    Mayawala K; Tse A; Rubin EH; Jain L; de Alwis DP
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S143-S145. PubMed ID: 28921649
    [No Abstract]   [Full Text] [Related]  

  • 11. Scaling adult dose and schedule of anticancer agents to children.
    Dawson TH
    J Cancer Res Clin Oncol; 2013 Dec; 139(12):2035-45. PubMed ID: 24072230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
    Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
    Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Flat-fixed dosing' of chemotherapy: a concept whose time has come?
    Markman M
    Curr Oncol Rep; 2005 Jan; 7(1):1-2. PubMed ID: 15610676
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of chemotherapy dose intensity on cancer patient outcomes.
    Lyman GH
    J Natl Compr Canc Netw; 2009 Jan; 7(1):99-108. PubMed ID: 19176210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring in cancer--are we missing a trick?
    Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
    Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.
    Zandvliet AS; Schellens JH; Beijnen JH; Huitema AD
    Clin Pharmacokinet; 2008; 47(8):487-513. PubMed ID: 18611060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.
    Chatelut E; White-Koning ML; Mathijssen RH; Puisset F; Baker SD; Sparreboom A
    Br J Cancer; 2012 Sep; 107(7):1100-6. PubMed ID: 22929884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy.
    Canal P; Gamelin E; Vassal G; Robert J
    Pathol Oncol Res; 1998; 4(3):171-8. PubMed ID: 9761935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifractionated dosing for cancer chemotherapy: a novel schedule and a work in progress.
    Lokich J
    Cancer Invest; 1999; 17(7):551-4. PubMed ID: 10518201
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
    Jones SF; Burris HA; Hainsworth JD; Yardley DA; Raefsky EA; Miranda FT; Kuzur ME; Willcutt NT; White MB; Greco FA
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):36-40. PubMed ID: 12800605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.